[go: up one dir, main page]

GB202004115D0 - Modified release formulations and dosage regimens - Google Patents

Modified release formulations and dosage regimens

Info

Publication number
GB202004115D0
GB202004115D0 GBGB2004115.8A GB202004115A GB202004115D0 GB 202004115 D0 GB202004115 D0 GB 202004115D0 GB 202004115 A GB202004115 A GB 202004115A GB 202004115 D0 GB202004115 D0 GB 202004115D0
Authority
GB
United Kingdom
Prior art keywords
release formulations
modified release
dosage regimens
regimens
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2004115.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invex Therapeutics Ltd
Original Assignee
Invex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invex Therapeutics Ltd filed Critical Invex Therapeutics Ltd
Priority to GBGB2004115.8A priority Critical patent/GB202004115D0/en
Publication of GB202004115D0 publication Critical patent/GB202004115D0/en
Priority to PCT/IB2021/052321 priority patent/WO2021186409A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2004115.8A 2020-03-20 2020-03-20 Modified release formulations and dosage regimens Ceased GB202004115D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2004115.8A GB202004115D0 (en) 2020-03-20 2020-03-20 Modified release formulations and dosage regimens
PCT/IB2021/052321 WO2021186409A1 (en) 2020-03-20 2021-03-19 Modified release formulations and dosage regimens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2004115.8A GB202004115D0 (en) 2020-03-20 2020-03-20 Modified release formulations and dosage regimens

Publications (1)

Publication Number Publication Date
GB202004115D0 true GB202004115D0 (en) 2020-05-06

Family

ID=70546673

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2004115.8A Ceased GB202004115D0 (en) 2020-03-20 2020-03-20 Modified release formulations and dosage regimens

Country Status (2)

Country Link
GB (1) GB202004115D0 (en)
WO (1) WO2021186409A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116891522B (en) * 2022-04-01 2024-05-14 南京知和医药科技有限公司 Long-acting glucagon-like peptide-1 derivative and preparation method and application thereof
AU2023375349A1 (en) * 2022-11-07 2025-05-22 AEON Biopharma, Inc. Compositions for use in treating headache disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114959A1 (en) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 Injectalble sustained-release pharmaceutical formulation and method for preparing it
KR101760953B1 (en) * 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. Sustained release formulations using non-aqueous carriers
RU2678833C2 (en) * 2008-09-17 2019-02-04 Киазма Инк. Pharmaceutical compositions and related delivery methods
CN103906528A (en) * 2011-06-24 2014-07-02 安米林药品有限责任公司 Methods of treating diabetes with sustained release formulations of GLP-1 receptor agonists
GB201415598D0 (en) * 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment

Also Published As

Publication number Publication date
WO2021186409A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
IL286847B1 (en) Hsp90-binding conjugates and formulations thereof
IL261700A (en) Formulations and doses of pegylated uricase
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
ZA201900275B (en) Oral gastroretentive formulations and uses thereof
IL277791A (en) Hsp90-targeting conjugates and formulations thereof
IL290513A (en) Formulations of benzazepine conjugates and uses thereof
ZA202400656B (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
IL288372A (en) Modified release formulations and uses thereof
IL280083A (en) Pharmaceutical dosage form which can be administered orally and has modified release
GB202019475D0 (en) Therapeutic compounds and their use
IL291543A (en) Therapeutic formulations and uses thereof
GB202108572D0 (en) Therapeutic compounds and their use
ZA202005143B (en) Oral formulations and uses thereof
GB202004115D0 (en) Modified release formulations and dosage regimens
IL299101A (en) Non-porcine formulations and methods thereof
GB2618737B (en) Modified release formulation comprising withanolides
PT3326619T (en) Solid oral pharmaceutical compositions comprising tenofovir and emtricitabine
GB202005282D0 (en) Pharmaceutical Formulations
MA43114A (en) FIXED-DOSE COMBINATION FORMULATION OF EFLORNITHIN AND SULINDAC
IL315222A (en) Therapeutic compounds, formulations, and use thereof
ZA202408364B (en) Liquid-dispersible halopyruvate formulations and associated methods
IL319382A (en) Pharmaceutical composition and use thereof
IL318364A (en) Therapeutic compounds, formulations, and use thereof
IL292646A (en) Pharmaceutical combination and use thereof
IL291196A (en) Drug dosage determination devices and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)